Evaluation of Resection Techniques for Pancreatic Tumors
The objective of this study is to compare open and minimally invasive pancreatic and liver resection techniques and analyze the different outcome variables from the clinical standpoint.
The plan is to investigate patient survival, length of stay, complication rates, operative time, transfusion rate, 30 and 90-day readmission rate, and hospital charges.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Colette N Ndjom, MS
- Phone Number: 74681 214-947-4681
- Email: ClinicalResearch@mhd.com
Study Contact Backup
- Name: Jennifer Kirchner
- Phone Number: 74459 214-947-4459
- Email: jenniferkirchner@mhd.com
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75203
- Recruiting
- Methodist Dallas Medical Center
-
Principal Investigator:
- Alejandro Mejia, MD
-
Contact:
- Jennifer Kirchner
- Phone Number: 74459 214-947-4459
- Email: jenniferkirchner@mhd.com
-
Contact:
- Colette N Ndjom, MS
- Phone Number: 71280 (214) 947-4681
- Email: mhsirb@mhd.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients that have undergone pancreatic or liver resection surgeries from January 2006 until December 2020 at Methodist Dallas Medical Center (MDMC)
- Patients 18 years old or older
Exclusion Criteria:
- Patients that have not undergone pancreatic resection surgeries
- Patients under 18 years of age
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Survival
Time Frame: through study completion, an average of 1 year
|
It will be calculated in days.Minimally invasive techniques are being adopted for complex pancreatic and liver surgery and there is a need to understand if these techniques are advantageous to the patient, if the cost is justified and if the risks are acceptable when compared to the gold standard open surgery.
|
through study completion, an average of 1 year
|
|
Length of stay
Time Frame: Up to 1 year
|
It will be calculated in days.
The days stayed in hospital post-procedure.
|
Up to 1 year
|
|
Complication rates
Time Frame: through study completion, an average of 1 year
|
Patient may visit physician or hospital for any symptoms or may need hospitalizations.
|
through study completion, an average of 1 year
|
|
Operative time
Time Frame: up to 10 hours
|
The time required for the procedure.
|
up to 10 hours
|
|
Transfusion rate
Time Frame: through study completion, an average of 1 year
|
If any post-procedure transfusion required, will be recorded.
|
through study completion, an average of 1 year
|
|
30 and 90 day readmission rate
Time Frame: through study completion, an average of 1 year
|
After the procedure any hospital admissions up to 30 days will be recorded.
|
through study completion, an average of 1 year
|
|
Hospital charges
Time Frame: through study completion, an average of 1 year
|
The hospital charges for the procedure will be recorded.
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Alejandro Mejia, M.D., The Liver Institute, Methodist Dallas Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Neoplasms by Site
- Neoplasms
- Neoplasms by Histologic Type
- Digestive System Neoplasms
- Digestive System Diseases
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Liver Diseases
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Pancreatic Neoplasms
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Peptide Hormones
- Peptides
- Amino Acids, Peptides, and Proteins
- Pancreatic Hormones
Other Study ID Numbers
Other Study ID Numbers
- 028.HPB.2016.D
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.